Marketing: Page 2
-
Rising insulin prices drive jump in diabetes treatment costs: report
Higher insulin spending accounted for nearly half of a $6,000 jump in per-person spending for Type 1 diabetes care between 2012 and 2016.
By Les Masterson • Jan. 23, 2019
-
Walgreens pays $270M to settle Medicaid fraud allegations
For years, the U.S. government alleges, the pharmacy giant routinely submitted false data to improperly secure federal reimbursement for insulin pens not needed by patients.
By Suzanne Elvidge • Jan. 23, 2019
-
FDA approves third biosimilar of Roche's Herceptin
The go-ahead creates yet another threat to one of the Swiss pharma's top-selling franchises.
By Suzanne Elvidge • Jan. 22, 2019
-
Lilly suspends Lartruvo promotion after Phase 3 failure
A miss on overall survival in the pharma's ANNOUNCE study calls into question the cancer drug's earlier accelerated approval.
By Jacob Bell • Jan. 18, 2019
-
Sandoz launches EpiPen rival at $250 per two-pack
The much-delayed launch has been a boost for originator Adamis Pharmaceuticals and provides a new competitor to the beleaguered EpiPen.
By Suzanne Elvidge • Jan. 18, 2019
-
7 biopharma trends to watch in 2019
Intensifying political pressure, surging cancer drug investment and the rise of pharma chief digital officers are among the factors which look set to shape the industry's next 12 months.
By Ned Pagliarulo • Jan. 17, 2019
-
Hospital drug spend spiked 19% from 2015-17, coalition says
The report, sponsored by hospital and pharmacy groups, is the latest attack in an ongoing battle over who should hold blame for high healthcare costs.
By Rebecca Pifer • Jan. 16, 2019
-
Allergan, Mohawk tribe ask for Supreme Court review of scrutinized patent case
A controversial deal designed to protect an Allergan top-seller from competition has so far proved for naught, but the two aim to continue their legal fight.
By Ned Pagliarulo • Jan. 16, 2019
-
Congressional investigation targets Pfizer, Novartis and J&J, among others
The new House Oversight chairman has asked 12 pharmas for pricing info on 18 top drugs, as Congress prepares to further scrutinize the industry.
By Andrew Dunn • Jan. 15, 2019
-
Louisiana launching 'Netflix model' in Medicaid for hep C drugs
The state is looking for a pharmaceutical partner on a project that will cap state spending for the expensive liver disease treatments.
By Les Masterson • Jan. 14, 2019
-
NICE turns down Novartis' Aimovig, flagging clinical trial concerns
The most clinically important patients were excluded from studies, the reviewing committee concluded in its draft decision to not recommend U.K. coverage of the migraine drug.
By Andrew Dunn • Jan. 11, 2019
-
J&J raises prices as Dems introduce bills aimed at lowering drug costs
Drug pricing reform has bipartisan support, but that hasn't stopped pharma from enacting hikes — in part because such moves have been vital to growth.
By Jacob Bell • Jan. 11, 2019
-
Grassley to zoom in on drug pricing, insurance mergers as Senate panel chair
The new Republican chairman of the Senate Finance Committee laid out his agenda, including allowing cheaper drug imports from Canada.
By David Lim • Jan. 10, 2019
-
As pharmas revert to regular price hikes, Azar threatens action with 'fighting words'
The Health and Human Services Secretary praised Merck & Co., Gilead Sciences and Amgen by name Wednesday on Twitter before declaring the industry "must stop" raising list prices.
By Andrew Dunn • Jan. 09, 2019
-
Bluebird proposes installment plan for LentiGlobin gene therapy
The biotech company would receive further payments only if LentiGlobin keeps working, according to a payment idea the company rolled out Tuesday.
By Kristin Jensen
-
Sponsored
Blockbuster … or lackluster? Four steps to a winning label
Do you have enough data to back-up how your product is better than others? Following these four steps can help you prepare for competition in the marketplace.
-
Pharma DTC spending outpaces rest of medical marketing, JAMA study finds
Companies spent $30 billion on medical marketing in 2016, up 60% from two decades ago. Direct-to-consumer spending more than tripled over that time.
By Andrew Dunn • Jan. 07, 2019
-
Esperion licenses European rights on cholesterol drug for $300M
While Esperion plans to file for approval in the first half of 2019, a long-term CV outcomes study lingers with an expected readout in 2022.
By Andrew Dunn • Jan. 04, 2019
-
Drugmakers open new year with price increases on dozens of medicines
Allergan, Biogen and Bristol-Myers were among the companies that raised list prices, suggesting criticism hasn't halted a return to "business as normal" for the industry.
By Ned Pagliarulo • Jan. 02, 2019
-
Acorda wins FDA nod for Parkinson's drug
An OK for Inbrija may help Acorda rebound from a damaging court ruling that opened the door for generic competition to the biotech's only marketed drug.
By Ned Pagliarulo • Dec. 24, 2018
-
Our 10 best stories of 2018
Pharma boards, cell therapy, AI and cancer drug ads feature in BioPharma Dive's top articles of the past 12 months.
By Ned Pagliarulo • Dec. 21, 2018
-
Gene therapy could be cost effective in SMA, but not at $4M
A report from ICER found Novartis' experimental Zolgensma could be more cost-effective than Biogen's Spinraza in treating spinal muscular atrophy.
By Ned Pagliarulo • Dec. 21, 2018
-
Trump drug ad proposal earns support from insurers, medical groups
Pharma strongly opposes the idea, however, arguing it would spark confusion and paint a misleading picture of what drugs end up costing consumers.
By Ned Pagliarulo • Dec. 19, 2018
-
Novartis, Pfizer withdraw drug applications in Europe
Novartis pulled canakinumab, with regulators leaning against approval, and Pfizer withdrew its Humira biosimilar.
By Andrew Dunn • Dec. 17, 2018
-
American leaders' distrust in science a 'dangerous situation,' BIO chair says
John Maraganore, the chair of biotech's largest trade group, said he's concerned the recent controversy over gene-edited babies could trigger knee-jerk reactions.
By Andrew Dunn • Dec. 14, 2018